Cantor Fitzgerald Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR)

Equities research analysts at Cantor Fitzgerald assumed coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a research report issued on Monday, MarketBeat Ratings reports. The brokerage set an "overweight" rating and a $74.00 price target on the stock. Cantor Fitzgerald's price target would suggest a potential upside of 93.41% from the stock's previous close. Cantor Fitzgerald also issued estimates for Monopar Therapeutics' FY2025 earnings at ($1.30) EPS and FY2026 earnings at ($3.09) EPS.

Other research analysts have also issued research reports about the stock. Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Chardan Capital initiated coverage on shares of Monopar Therapeutics in a research note on Monday, June 23rd. They issued a "buy" rating and a $60.00 price objective for the company. Piper Sandler reissued an "overweight" rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Finally, Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Monopar Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.00.

Monopar Therapeutics Stock Down 5.4%

MNPR stock traded down $2.18 during mid-day trading on Monday, hitting $38.26. 35,147 shares of the company were exchanged, compared to its average volume of 359,983. The firm has a market capitalization of $233.96 million, a P/E ratio of -10.99 and a beta of 1.01. The business has a fifty day simple moving average of $35.81 and a 200-day simple moving average of $35.32. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.27. Research analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently added to or reduced their stakes in MNPR. Janus Henderson Group PLC acquired a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $23,435,000. Adage Capital Partners GP L.L.C. acquired a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $13,182,000. RA Capital Management L.P. acquired a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. Point72 Asset Management L.P. acquired a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $2,861,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.